Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
64 hedge funds and large institutions have $107M invested in Poseida Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 14 closing their positions.
3% less funds holding
Funds holding: 66 → 64 (-2)
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
24% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 21
40% less capital invested
Capital invested by funds: $178M → $107M (-$71.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$692K |
| 2 |
CC
Corton Capital
Carrying Place,
Ontario, Canada
|
+$262K |
| 3 |
MA
MCF Advisors
Covington,
Kentucky
|
+$259K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$213K |
| 5 |
DU
Delphia (USA)
Toronto,
Ontario, Canada
|
+$184K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
-$11.6M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.42M |
| 3 |
PVI
Pura Vida Investments
New York
|
-$612K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$577K |
| 5 |
BlackRock
New York
|
-$379K |
PSTX Hedge Fund Activity: Q1 2022 in Review
64 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q1 2022, worth a combined $107M — down 40% from $178M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PSTX and 12 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 16 added.
The largest buyer was Renaissance Technologies, adding an estimated $692K. The largest seller was Natixis, exiting entirely with an estimated $11.6M sold.
- 64 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q1 2022, down from 66 in Q4 2021.
- Funds reported $107M of Poseida Therapeutics, Inc. Common Stock stock for Q1 2022, down 40% quarter-over-quarter.
- 12 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q1 2022 and 14 closed out, a net change of -2 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $692K added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q1 2022 was Natixis, an estimated $11.6M sold.
Based on aggregated 13F filings for Q1 2022.